Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Golan et al. (Sun,) studied this question.

synapsesocial.com/papers/69d70f295413bc3de5ab3519 https://doi.org/https://doi.org/10.1056/nejmoa1903387

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Maintenance therapy in ovarian cancer2014 · 25 citations
2Geographic and ethnic heterogeneity in the <i>BRCA1/2</i> pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).2018 · 20 citations
3FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).2018 · 53 citations
4Genetic predisposition to pancreatic cancer2014 · 99 citations
5Nonparametric Estimation from Incomplete Observations1992 · 45,545 citations

Bookmark

View Full Paper